ArticlePloS one2026
Tertiary-care management of TB/HIV co-infection in Port Harcourt, Nigeria: A retrospective cohort analysis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMonitoring the treatment of tuberculosis(TB) and human immunodeficiency virus(HIV) co-infection is very important to improve patient management and compliance; however, treatment outcome monitoring remains inadequate in Nigeria. This study assessed the treatment outcomes of registered TB/HIV co-infected patients enrolled in the Directly Observed Treatment Short course(DOTS) program.
methodsA retrospective study was conducted in a tertiary-care hospital in Port Harcourt, Nigeria from January 1, 2014 to December 31, 2019. Data were extracted from the National TB program register and analyzed using the statistical software package(IBM SPSS version30.0). Bivariate and multivariate logistic regressions were used to identify factors associated with treatment outcomes at 95% confidence intervals.
resultsAmong 305(37.4%) TB/HIV co-infected patients, the mean age was 29.2years, with 29.8% in the 0-14 age group, 89.5% new cases, and 89.2% pulmonary TB(PTB) cases. Males(50.2%) slightly outnumbered females(49.8%). Antiretroviral therapy(ART) and cotrimoxazole preventive therapy(CPT) uptake were high(95.1% and 93.4%, respectively). Treatment outcomes were: 19.0% cured, 23.3% completed treatment, 0.3% failed treatment, 23.6% died, 14.8% lost to follow-up, 10.8% transferred out, and 8.2% not evaluated. Overall, treatment success rate was 52.2%. Age(15-24 years: adjusted odds ratio [AOR]=6.35, 95%CI:1.56-25.86; 25-34 years: AOR = 3.97, 95%CI:1.37-11.45; and 45-54 years: AOR = 6.40, 95%CI:2.27-18.06) and alternative diagnostic method(AOR = 0.32, 95%CI:0.12-0.76) were significantly associated with unsuccessful treatment outcomes.
conclusionThe treatment success rate of TB/HIV co-infected patients was relatively low and fell below the World Health Organization's (WHO) target despite high uptake of ART and CPT. Study underscores the need for integrating targeted interventions, including alternative diagnostic methods, into clinical practice and policy to improve treatment outcomes among TB/HIV co-infected patients, particularly in specific age groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.